Does exenatide at the time of primary PCI improve long-term prognosis in patients with STEMI?
In patients with STEMI undergoing primary PCI, exenatide did not improve the primary composite endpoint or mortality, but may reduce heart failure admissions.
In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.
Kyhl et al. (Fri,) studied this question.